NAV-003, A Bispecific Antibody Targeting A Unique Mesothelin Epitope and CD3ε With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of immunology"
DOI: 10.1002/eji.202250309
Abstract: Mesothelin (MSLN) is a cell surface protein over-expressed in a number of cancer types. Several antibody- and cellular-based MSLN targeting agents have been tested in clinical trials where their therapeutic efficacy has been moderate at… read more here.
Keywords: cd3; mesothelin; bispecific antibody; nav 003 ... See more keywords
Gold-coated nanoporous polycarbonate track–etched solid platform for the rapid detection of mesothelin
Sign Up to like & getrecommendations! Published in 2018 at "Ionics"
DOI: 10.1007/s11581-018-2761-6
Abstract: Gold nanolayer—coated polycarbonate track–etched membrane (PCTE)–based microfluidic electrochemical biosensor grown on a highly interactive sandwich-like nanolayer has been designed. The gold nanolayer behaves like a sandwich further underwent thiol modification, EDC/NHS chemistry endowed excellent interaction… read more here.
Keywords: track etched; polycarbonate track; mesothelin; gold ... See more keywords
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
Sign Up to like & getrecommendations! Published in 2017 at "Protein & Cell"
DOI: 10.1007/s13238-017-0472-9
Abstract: Pancreatic cancer is a devastating disease ranked as the 4th leading cause of cancer-related deaths in the United States, and its incidence rate is increasing according to the latest statistics. The overall survival rates for… read more here.
Keywords: msln; pancreatic cancer; mesothelin; cancer ... See more keywords
Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Cellular immunology"
DOI: 10.1016/j.cellimm.2018.04.007
Abstract: Patients with pancreatic cancer have a poor prognosis largely due to the poor efficacy of the available treatment modalities. In this study, we engineered mesothelin-targeting chimeric antigen receptor T cells (mesoCAR T) using the piggyBac… read more here.
Keywords: cancer; mesothelin; piggybac transposon; pancreatic cancer ... See more keywords
Construction of a 124I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00342
Abstract: Mesothelin (MSLN) is a molecular biomarker of many types of solid tumors, such as mesothelioma, pancreatic cancer, and colon cancer. Owing to the significant difference in expression between cancer cells and normal cells, mesothelin has… read more here.
Keywords: mesothelin; anti msln; 124i anti; msln ... See more keywords
Construction and Preclinical Evaluation of a 124/131I-labeled radiotracer for the Detection of Mesothelin-Overexpressing Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.9b01281
Abstract: Mesothelin is a molecular biomarker of many types of solid cancers, which may represent a highly promising new target in the development of cancer-targeted diagnostic agents. A human anti-mesothelin antibody with a low molecular weight,… read more here.
Keywords: labeled radiotracer; 124 131i; mesothelin; 131i labeled ... See more keywords
Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-94902-1
Abstract: Mesothelin (MSLN) is an attractive candidate of targeted therapy for several cancers, and hence there are increasing needs to develop MSLN-targeting strategies for cancer therapeutics. Antibody–drug conjugates (ADCs) targeting MSLN have been demonstrated to be… read more here.
Keywords: optimized anti; drug conjugates; antibody; human gastric ... See more keywords
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients with Esophageal Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of surgery"
DOI: 10.1097/sla.0000000000005885
Abstract: OBJECTIVE We conducted a prospective trial (NCT01393483) to investigate the utility of serum soluble mesothelin related peptide (SMRP) and tumor mesothelin expression in the management of esophageal adenocarcinoma (ADC). SUMMARY BACKGROUND DATA Clinical management of… read more here.
Keywords: mesothelin; treatment; mesothelin expression; tumor mesothelin ... See more keywords
Novel single‐chain variant of antibody against mesothelin established by phage library
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Science"
DOI: 10.1111/cas.14150
Abstract: Mesothelin (MSLN) shows increased expression in various cancer cells. For clinical application of antibodies as a positron emission tomography (PET) imaging reagent, a human shortened antibody is essential both for avoiding redundant immune responses and… read more here.
Keywords: msln; phage; phage library; scfv ... See more keywords
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003927
Abstract: Objectives Anetumab ravtansine is an antibody-drug conjugate consisting of a fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4. Mesothelin is highly expressed in ovarian cancer. This phase Ib study determines the… read more here.
Keywords: mesothelin; anetumab ravtansine; ovarian cancer; pegylated liposomal ... See more keywords
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-1181
Abstract: Purpose: To assess the safety and tolerability of BMS-986148, a mesothelin-directed antibody–drug conjugate (ADC) ± nivolumab, in patients with selected tumors. Patients and Methods: In an international phase I/IIa study [NCT02341625 (CA008-002)], patients received BMS-986148… read more here.
Keywords: bms; every weeks; antibody drug; 986148 nivolumab ... See more keywords